P2D Bioscience (P2D) is a specialty pharmaceutical company focused on developing innovative drugs that fulfill unmet medical needs in the treatment of central nervous system (CNS) and pulmonary disorders including attention deficit/hyperactivity disorder (ADHD), obesity, anxiety, depression, Alzheimer’s disease, traumatic brain injury and chronic obstructive pulmonary disease (COPD). At P2D, our experienced drug development team utilizes our in-depth understanding of the clinical treatment of CNS disorders and neurodegenerative diseases to efficiently build a product portfolio of therapeutics with an improved likelihood for clinical success. Our goal is to advance a product candidate through preclinical development and clinical proof-of-concept by producing powerful and compelling clinical data and then seeking partners to complete the clinical development and commercialization process. P2D currently has a pipeline of nine drug candidates to treat ADHD, obesity and diabetes, Alzheimer’s disease, traumatic brain injury and COPD.
There is no investment information
No recent news or press coverage available for P2D Bioscience.
We care about your data, and we'd love to use cookies make your experience better.
